NASDAQ:ZYNE

Zynerba Pharmaceuticals Competitors

$3.81
-0.07 (-1.80 %)
(As of 04/20/2021 03:59 PM ET)
Add
Compare
Today's Range
$3.69
Now: $3.81
$3.89
50-Day Range
$3.97
MA: $4.60
$7.03
52-Week Range
$3.12
Now: $3.81
$9.00
Volume45,662 shs
Average Volume4.89 million shs
Market Capitalization$157.17 million
P/E RatioN/A
Dividend YieldN/A
Beta2.83

Competitors

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Vs. KDMN, GOSS, ALBO, EVLO, CLVS, and OGI

Should you be buying ZYNE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Zynerba Pharmaceuticals, including Kadmon (KDMN), Gossamer Bio (GOSS), Albireo Pharma (ALBO), Evelo Biosciences (EVLO), Clovis Oncology (CLVS), and OrganiGram (OGI).

Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Kadmon (NASDAQ:KDMN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Zynerba Pharmaceuticals and Kadmon, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zynerba Pharmaceuticals01502.83
Kadmon00503.00

Zynerba Pharmaceuticals currently has a consensus price target of $13.65, suggesting a potential upside of 261.11%. Kadmon has a consensus price target of $12.75, suggesting a potential upside of 232.90%. Given Zynerba Pharmaceuticals' higher possible upside, research analysts clearly believe Zynerba Pharmaceuticals is more favorable than Kadmon.

Profitability

This table compares Zynerba Pharmaceuticals and Kadmon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zynerba PharmaceuticalsN/A-60.20%-52.40%
Kadmon-768.36%-85.07%-46.46%

Risk & Volatility

Zynerba Pharmaceuticals has a beta of 2.83, indicating that its stock price is 183% more volatile than the S&P 500. Comparatively, Kadmon has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500.

Institutional & Insider Ownership

26.0% of Zynerba Pharmaceuticals shares are held by institutional investors. Comparatively, 94.8% of Kadmon shares are held by institutional investors. 11.1% of Zynerba Pharmaceuticals shares are held by company insiders. Comparatively, 3.0% of Kadmon shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Zynerba Pharmaceuticals and Kadmon's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zynerba Pharmaceuticals$90,000.001,746.33$-32,940,000.00($1.50)-2.54
Kadmon$5.09 million129.28$-61,370,000.00($0.74)-5.18

Zynerba Pharmaceuticals has higher earnings, but lower revenue than Kadmon. Kadmon is trading at a lower price-to-earnings ratio than Zynerba Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Zynerba Pharmaceuticals beats Kadmon on 8 of the 13 factors compared between the two stocks.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Zynerba Pharmaceuticals and Gossamer Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zynerba Pharmaceuticals01502.83
Gossamer Bio00503.00

Zynerba Pharmaceuticals currently has a consensus price target of $13.65, suggesting a potential upside of 261.11%. Gossamer Bio has a consensus price target of $23.00, suggesting a potential upside of 182.90%. Given Zynerba Pharmaceuticals' higher possible upside, research analysts clearly believe Zynerba Pharmaceuticals is more favorable than Gossamer Bio.

Profitability

This table compares Zynerba Pharmaceuticals and Gossamer Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zynerba PharmaceuticalsN/A-60.20%-52.40%
Gossamer BioN/A-64.34%-46.52%

Risk & Volatility

Zynerba Pharmaceuticals has a beta of 2.83, indicating that its stock price is 183% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.

Institutional & Insider Ownership

26.0% of Zynerba Pharmaceuticals shares are held by institutional investors. Comparatively, 72.0% of Gossamer Bio shares are held by institutional investors. 11.1% of Zynerba Pharmaceuticals shares are held by company insiders. Comparatively, 23.3% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Zynerba Pharmaceuticals and Gossamer Bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zynerba Pharmaceuticals$90,000.001,746.33$-32,940,000.00($1.50)-2.54
Gossamer BioN/AN/A$-180,310,000.00($3.29)-2.50

Zynerba Pharmaceuticals has higher revenue and earnings than Gossamer Bio. Zynerba Pharmaceuticals is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Zynerba Pharmaceuticals beats Gossamer Bio on 7 of the 11 factors compared between the two stocks.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Albireo Pharma (NASDAQ:ALBO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Zynerba Pharmaceuticals and Albireo Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zynerba Pharmaceuticals01502.83
Albireo Pharma00803.00

Zynerba Pharmaceuticals currently has a consensus price target of $13.65, suggesting a potential upside of 261.11%. Albireo Pharma has a consensus price target of $72.00, suggesting a potential upside of 130.11%. Given Zynerba Pharmaceuticals' higher possible upside, research analysts clearly believe Zynerba Pharmaceuticals is more favorable than Albireo Pharma.

Profitability

This table compares Zynerba Pharmaceuticals and Albireo Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zynerba PharmaceuticalsN/A-60.20%-52.40%
Albireo Pharma-751.53%-71.22%-42.91%

Risk & Volatility

Zynerba Pharmaceuticals has a beta of 2.83, indicating that its stock price is 183% more volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Institutional & Insider Ownership

26.0% of Zynerba Pharmaceuticals shares are held by institutional investors. Comparatively, 85.7% of Albireo Pharma shares are held by institutional investors. 11.1% of Zynerba Pharmaceuticals shares are held by company insiders. Comparatively, 5.0% of Albireo Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Zynerba Pharmaceuticals and Albireo Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zynerba Pharmaceuticals$90,000.001,746.33$-32,940,000.00($1.50)-2.54
Albireo Pharma$9.64 million62.54$-62,720,000.00($5.04)-6.26

Zynerba Pharmaceuticals has higher earnings, but lower revenue than Albireo Pharma. Albireo Pharma is trading at a lower price-to-earnings ratio than Zynerba Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Zynerba Pharmaceuticals beats Albireo Pharma on 9 of the 14 factors compared between the two stocks.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Zynerba Pharmaceuticals and Evelo Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zynerba Pharmaceuticals01502.83
Evelo Biosciences02302.60

Zynerba Pharmaceuticals currently has a consensus price target of $13.65, suggesting a potential upside of 261.11%. Evelo Biosciences has a consensus price target of $20.00, suggesting a potential upside of 83.49%. Given Zynerba Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Zynerba Pharmaceuticals is more favorable than Evelo Biosciences.

Profitability

This table compares Zynerba Pharmaceuticals and Evelo Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zynerba PharmaceuticalsN/A-60.20%-52.40%
Evelo BiosciencesN/A-159.17%-88.81%

Risk & Volatility

Zynerba Pharmaceuticals has a beta of 2.83, indicating that its stock price is 183% more volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500.

Institutional & Insider Ownership

26.0% of Zynerba Pharmaceuticals shares are held by institutional investors. Comparatively, 84.6% of Evelo Biosciences shares are held by institutional investors. 11.1% of Zynerba Pharmaceuticals shares are held by company insiders. Comparatively, 7.3% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Zynerba Pharmaceuticals and Evelo Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zynerba Pharmaceuticals$90,000.001,746.33$-32,940,000.00($1.50)-2.54
Evelo BiosciencesN/AN/A$-85,470,000.00($2.67)-4.07

Zynerba Pharmaceuticals has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Zynerba Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Zynerba Pharmaceuticals beats Evelo Biosciences on 11 of the 12 factors compared between the two stocks.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Institutional & Insider Ownership

26.0% of Zynerba Pharmaceuticals shares are held by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are held by institutional investors. 11.1% of Zynerba Pharmaceuticals shares are held by company insiders. Comparatively, 6.6% of Clovis Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Zynerba Pharmaceuticals and Clovis Oncology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zynerba Pharmaceuticals01502.83
Clovis Oncology12202.20

Zynerba Pharmaceuticals currently has a consensus price target of $13.65, suggesting a potential upside of 261.11%. Clovis Oncology has a consensus price target of $9.50, suggesting a potential upside of 71.79%. Given Zynerba Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Zynerba Pharmaceuticals is more favorable than Clovis Oncology.

Profitability

This table compares Zynerba Pharmaceuticals and Clovis Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zynerba PharmaceuticalsN/A-60.20%-52.40%
Clovis Oncology-230.34%N/A-57.56%

Earnings and Valuation

This table compares Zynerba Pharmaceuticals and Clovis Oncology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zynerba Pharmaceuticals$90,000.001,746.33$-32,940,000.00($1.50)-2.54
Clovis Oncology$143.01 million4.14$-400,420,000.00($7.60)-0.74

Zynerba Pharmaceuticals has higher earnings, but lower revenue than Clovis Oncology. Zynerba Pharmaceuticals is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Zynerba Pharmaceuticals has a beta of 2.83, indicating that its stock price is 183% more volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.

Summary

Zynerba Pharmaceuticals beats Clovis Oncology on 10 of the 14 factors compared between the two stocks.

OrganiGram (NASDAQ:OGI) and Zynerba Pharmaceuticals (NASDAQ:ZYNE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Insider and Institutional Ownership

10.8% of OrganiGram shares are held by institutional investors. Comparatively, 26.0% of Zynerba Pharmaceuticals shares are held by institutional investors. 11.1% of Zynerba Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for OrganiGram and Zynerba Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OrganiGram06402.40
Zynerba Pharmaceuticals01502.83

OrganiGram currently has a consensus target price of $4.4113, suggesting a potential upside of 86.92%. Zynerba Pharmaceuticals has a consensus target price of $13.65, suggesting a potential upside of 261.11%. Given Zynerba Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Zynerba Pharmaceuticals is more favorable than OrganiGram.

Profitability

This table compares OrganiGram and Zynerba Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrganiGram-207.26%-10.00%-7.14%
Zynerba PharmaceuticalsN/A-60.20%-52.40%

Valuation & Earnings

This table compares OrganiGram and Zynerba Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrganiGram$64.61 million8.38$-101,290,000.00($0.08)-29.13
Zynerba Pharmaceuticals$90,000.001,746.33$-32,940,000.00($1.50)-2.54

Zynerba Pharmaceuticals has lower revenue, but higher earnings than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than Zynerba Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

OrganiGram has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Zynerba Pharmaceuticals has a beta of 2.83, suggesting that its share price is 183% more volatile than the S&P 500.

Summary

Zynerba Pharmaceuticals beats OrganiGram on 10 of the 14 factors compared between the two stocks.


Zynerba Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kadmon logo
KDMN
Kadmon
1.8$3.83-3.1%$637.44 million$5.09 million-6.38
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.21-1.9%$632.17 millionN/A-2.31Increase in Short Interest
News Coverage
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$31.54-4.3%$628.85 million$9.64 million-5.14
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.86-6.4%$616.02 millionN/A-4.36Analyst Upgrade
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.66-2.1%$604.18 million$143.01 million-1.08
OrganiGram logo
OGI
OrganiGram
1.6$2.33-11.6%$603.91 million$64.61 million-3.43Analyst Downgrade
Decrease in Short Interest
Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.95-0.9%$595.21 million$8 million-8.10
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.56-1.0%$592.94 millionN/A-9.87Analyst Report
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.55-2.3%$591.17 million$59.29 million-23.67Increase in Short Interest
News Coverage
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$34.65-0.5%$577.60 millionN/A-16.04
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$42.87-0.6%$563.31 million$195.89 million122.49
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$23.72-2.5%$562.00 million$12.69 million-11.40Increase in Short Interest
News Coverage
Gap Up
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.57-5.2%$551.05 million$26.74 million18.93News Coverage
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$17.85-0.7%$547.04 millionN/A-5.19
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.58-2.5%$534.08 million$1.19 million-6.91
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.83-0.9%$521.18 millionN/A-4.63News Coverage
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.4$11.01-1.0%$518.23 millionN/A-8.53
Inventiva logo
IVA
Inventiva
0.0$13.39-0.4%$517.26 millionN/A0.00Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$13.84-1.3%$513.60 millionN/A-3.99
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.04-0.2%$510.88 million$25 million-18.52
Provention Bio logo
PRVB
Provention Bio
1.6$7.82-2.9%$510.17 millionN/A-5.25Analyst Report
Increase in Short Interest
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.58-0.8%$509.84 millionN/A-5.43
89bio logo
ETNB
89bio
1.6$25.93-2.4%$505.03 millionN/A-5.13Insider Selling
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.68-3.1%$498.07 millionN/A-8.14
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.17-3.7%$495.20 million$59.22 million40.85
XBiotech logo
XBIT
XBiotech
1.0$16.43-2.0%$493.73 millionN/A1.14News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.50-1.9%$493.31 million$58.12 million-15.70
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.99-4.9%$492.36 million$57.49 million-6.71News Coverage
Gap Up
Akouos logo
AKUS
Akouos
1.6$14.50-1.7%$490.23 millionN/A0.00
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$33.41-7.1%$483.22 million$40,000.00-1.45Upcoming Earnings
Gap Up
AC Immune logo
ACIU
AC Immune
1.3$6.51-0.0%$468.31 million$111.75 million-7.23Analyst Revision
Gap Up
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.94-4.4%$464.67 million$22.27 million-3.89Analyst Revision
News Coverage
Evolus logo
EOLS
Evolus
1.5$10.53-0.9%$464.44 million$34.92 million-5.19Gap Up
Verastem logo
VSTM
Verastem
1.3$2.73-1.1%$463.50 million$17.46 million-1.94
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.18-1.7%$456.10 million$49.65 million-1.66
Verona Pharma logo
VRNA
Verona Pharma
1.7$7.73-0.1%$448.42 millionN/A-2.35
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.39-1.8%$447.49 million$102.31 million6.55Increase in Short Interest
News Coverage
Geron logo
GERN
Geron
1.4$1.40-0.0%$445.94 million$460,000.00-4.00Decrease in Short Interest
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.90-0.3%$444.27 million$109.33 million-2.13
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.80-1.6%$440.69 millionN/A-11.84News Coverage
Altimmune logo
ALT
Altimmune
1.9$11.81-0.3%$437.63 million$5.80 million-5.93
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$2.83-0.7%$437.48 million$335 million-0.96
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.6$8.61-1.7%$437.33 million$72.96 million-2.79Analyst Report
News Coverage
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.01-0.9%$435.17 million$6.07 million-3.35News Coverage
MedAvail logo
MDVL
MedAvail
1.9$12.82-4.7%$428.64 million$1.03 million-3.14Gap Up
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$3.67-3.8%$428.14 million$6.68 million-4.42Gap Up
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$16.40-0.3%$427.85 millionN/A-3.45
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.12-0.6%$427.02 million$56.50 million0.00
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$18.20-0.3%$425.87 millionN/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.